Video transcript
On Screen Text
Respiratory syncytial virus (RSV) infection typically causes mild cold-like symptoms including runny nose, sore throat, cough, and headache.1,2 But in older adults and adults with certain underlying conditions it can progress to more severe disease involving the lower respiratory tract.3
Michele is a patient advocate who has experienced RSV and is speaking to her personal experience with RSV. Others' experiences with RSV may be different. She was compensated by GSK for her participation in this program.
Lower Third Text
Audio
My name is Michele. I'm 54 years old and I'm a respiratory therapist. I live in New Jersey with my husband and my daughter. I've had asthma since childhood and I manage it on a daily basis. Some days I have trouble breathing, I can’t catch my breath. It feels like a tightness in my chest.
Two years ago, when I was 52, I started having what I thought was cold symptoms. I was a little congested, runny nose. But I felt okay. I went along doing the things I normally do.
After a few days of trying to manage my symptoms with over-the-counter medications and my asthma medications, I started to get worse.
I had more fatigue and a fever, got worse. And my husband decided that we needed to go to the hospital.
On Screen Text
RSV is usually mild, though in older adults and adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD), or chronic heart failure (CHF), it can sometimes be severe.3
Audio
At the hospital, they diagnosed me with RSV and they did a chest x-ray and told me I had pneumonia. The doctors said most likely I contracted RSV first and then I got the pneumonia. So they admitted me to take care of me.
My asthma just made everything so much worse that I had to stay there for several days.
When I got home, it took me much longer to recover. I was sick at home for a while, unable to do a lot.
On Screen Text
Most RSV infections go away on their own in a week or two.2
Audio
My lungs were weak. I could barely breathe. Plus the fatigue and the headaches kept me in bed all day.
I got out of the hospital the day before my daughter came home from college to celebrate her 21st birthday. And that's a big birthday. You only get one of those. And I was too sick to really celebrate with her. I was in the hospital in the beginning of December. So I was too sick to do the things to get ready for the holidays. We enjoy baking for the holidays. I didn't have any energy to be able to do that with my daughter.
Missing out on the, the holidays and being so sick just makes me really appreciate, you know, when I am feeling well and I get to do the things that I enjoy doing like cooking with my family, like gardening, like spending time going to concerts and being with my friends. When you're sick in the hospital like that, you just miss out on so much.
For most people, RSV is like a common cold, for older people and people with underlying conditions like myself with my asthma, it can be much worse.
RSV vaccination is available for appropriate individuals. When I got sick, it wasn't. If I ever were to get RSV again, I want to know that I took all the steps in my power to potentially prevent severe RSV. And for me, that starts with vaccination.
On Screen Text
AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) logo
AREXVY was the first RSV vaccine approved for patients 50-59 years of age who are at increased risk for RSV-LRTD.4
Audio and On Screen Text
Indication for AREXVY
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:
- individuals 60 years of age and older;
- individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
Important Safety Information for AREXVY
- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with AREXVY
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
- In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients
Please see full Prescribing Information for AREXVY on this website.
Visit AREXVYHCP.com for more information.
On Screen Text
AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)/GSK logo lockup
References: 1. Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV): About RSV. Reviewed August 30, 2024. Accessed January 9, 2025. https://www.cdc.gov/rsv/about/index.html 2. Centers for Disease Control and Prevention. Symptoms and Care of RSV. Reviewed August 30, 2024. Accessed January 9, 2025. https://www.cdc.gov/rsv/symptoms/index.html 3. Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV): RSV in Older Adults. Reviewed August 30, 2024. Accessed January 9, 2025. https://www.cdc.gov/rsv/older- adults/index.html 4. Prescribing Information for AREXVY.
Intended for US healthcare professionals only.
Trademarks are owned by or licensed to the GSK group of companies.
©2025 GSK or licensor.
PMUS-RSAVID240047 January 2025
Produced in USA.
close